• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

October 15, 2014 By Celyad

ont-Saint-Guibert, Belgium – Mayo Clinic and Cardio3 Biosciences recently entered into a non-exclusive preferred access agreement. This agreement builds on a long established and productive relationship of licensing and research in the area of cardiac regeneration. The mutual hope for this work is that together Mayo Clinic and Cardio3 BioSciences can accelerate Mayo Clinic discoveries toward clinical application.

Under the collaboration agreement, the parties have agreed to regular periodic meetings to review Mayo Clinic’s regenerative medicine portfolio to identify areas and projects of mutual interest. The results of these conversations could potentially lead to cooperative research projects, license agreements or introductions to third parties to further the technology. The agreement does not prevent Mayo Clinic from working with other potential commercial partners in the same manner.

Mayo Clinic and Cardio3 BioSciences look forward to this ongoing collaboration and both believe that together they can continue to move promising technologies towards patients.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy